Our recent game-changing investments include:

**Preventive treatments**
Protection for pregnant women in sub-Saharan Africa and long-acting seasonal prevention for small children in the Sahel region
$61 m

**Vaccine**
Piloting the world’s first malaria vaccine in three high-malaria countries in Africa
$10 m

**Treatment**
Expanding access to severe malaria interventions including rectal artesunate as an emergency referral measure
$33 m

**Vector control tools**
Protecting families with new insecticide treated nets and indoor sprays, mosquito-repellent sheets for indoor and outdoor protection, and a drug for humans and livestock that kills mosquitoes
$190 m

**Integrated fever approaches**
Increasing access to portable devices that can detect signs of life-threatening febrile illnesses (e.g. severe malaria and severe pneumonia)
$43 m

**Our portfolio keeps growing**
Future investments being explored include expanding integrated approaches, eliminating *Plasmodium vivax* malaria and increasing access to preventive treatments for infants. We continue to provide funding for WHO’s prequalification program.

Unitaid’s current main funders are France, the United Kingdom, Brazil, Norway, Chile, the Republic of Korea, Spain and the Bill & Melinda Gates Foundation. Unitaid is a hosted partnership of the World Health Organization.